ORIGINAL ARTICLE |
|
Year : 2019 | Volume
: 44
| Issue : 1 | Page : 16-20 |
|
Validation of three-dimensional electronic portal imaging device-based PerFRACTION™ software for patient-specific quality assurance
A Aziz Sait1, Jason Figueredo2, Glenn W Jones3, Kai Jones4, Thomas McGowan1, Jeff Kapatoes2, Ramani Ramaseshan5
1 Department of Radiation Oncology, The Cancer Centre Eastern Caribbean, St. John's, Antigua 2 Sun Nuclear Corporation, Melbourne, FL, USA 3 School of Clinical Medicine and Research, University of West Indies, Nassau, The Bahamas 4 Vagelos College of Physicians and Surgeons, Columbia University, New York City, New York, USA 5 Department of Medical Physics, BC Cancer Agency-Abbotsford Cancer Center, British Columbia, Canada
Correspondence Address:
Dr. Ramani Ramaseshan Department of Medical Physics, BC Cancer Agency-Abbotsford Cancer Center, British Columbia V2S 0C2 Canada
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jmp.JMP_76_18
|
|
Purpose: PerFRACTION™ is a three-dimensional (3D) in vivo electronic portal imaging device-based dosimetry software. To validate the software, three phantoms with different inserts (2D array, ionization chamber, and inhomogeneity materials) were constructed to evaluate point dose and fluence map. Materials and Methods: Phantoms underwent independent computed tomography simulation for planning and received repetitive fractions of volumetric modulated arc therapy, simulating prostate treatment. Fluence and absolute point dose measurements, PerFRACTION™ reconstructed doses, and the dose predictions of the planning system were compared. Results: There was concordance between ionization chamber and PerFRACTION™ 3D absolute point dose measurements. Close agreement was also obtained between X- and Y-axis dose profiles with PerFRACTION™ calculated doses, MapCHECK measured doses, and planning system predicted doses. Setup shifts significantly influenced 2D gamma passing rates in PerFRACTION™ software. Conclusions: PerFRACTIONTM appears reliable and valid under experimental conditions in air and with phantoms. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|